An FDA advisory panel voted on Thursday to modify restrictions on the much-embattled diabetes drug rosiglitazone (Avandia), Reuters reports.

There were 13 votes in favor of changing the restrictions, seven votes to remove the restrictions entirely, and five to leave the restrictions as they are. One adviser voted to withdraw the drug from the market altogether. The extent of the proposed modifications is unknown at present.

Rosiglitazone’s use is currently limited to patients who are already taking the drug and to those whose diabetes is not controlled by other treatments and who do not want to take pioglitazone.

Source: FDA